Heribert Stoiber1. 1. Section of Hygiene & Microbiology, Innsbruck Medical University, Innsbruck, Austria. hygiene@i-med.ac.at
Abstract
PURPOSE OF REVIEW: Because complement is present in all fluids of the body, including serum, saliva and seminal fluid, and is found at mucosal surfaces and in the brain, all pathogens have to deal with complement proteins. Thus, immediately upon entering the host, independent on the route of infection, HIV activates the complement system. Although a first line of immune defense, complement cannot eliminate retroviral infections completely. RECENT FINDINGS: Recent data indicate that complement, in concert with non-neutralizing antibodies, contributes to the control of HIV replication at early stages of infection. In parallel or at later stages, complement and non-neutralizing antibodies may counteract the immune response by enhancing HIV infection via complement and Fc-receptor-positive cells in 'cis' and 'trans'. SUMMARY: This review highlights current knowledge in this field and emphasizes the contribution of complement and non-neutralizing antibodies in controlling versus and enhancing infection.
PURPOSE OF REVIEW: Because complement is present in all fluids of the body, including serum, saliva and seminal fluid, and is found at mucosal surfaces and in the brain, all pathogens have to deal with complement proteins. Thus, immediately upon entering the host, independent on the route of infection, HIV activates the complement system. Although a first line of immune defense, complement cannot eliminate retroviral infections completely. RECENT FINDINGS: Recent data indicate that complement, in concert with non-neutralizing antibodies, contributes to the control of HIV replication at early stages of infection. In parallel or at later stages, complement and non-neutralizing antibodies may counteract the immune response by enhancing HIV infection via complement and Fc-receptor-positive cells in 'cis' and 'trans'. SUMMARY: This review highlights current knowledge in this field and emphasizes the contribution of complement and non-neutralizing antibodies in controlling versus and enhancing infection.
Authors: Eun Mi Hur; Sonal N Patel; Saki Shimizu; Dinesh S Rao; Priyanthi N P Gnanapragasam; Dong Sung An; Lili Yang; David Baltimore Journal: Blood Date: 2012-10-11 Impact factor: 22.113
Authors: Thavamalar Balakrishnan; Dennis B Bela-Ong; Ying Xiu Toh; Marie Flamand; Shamala Devi; Mickey B Koh; Martin L Hibberd; Eng Eong Ooi; Jenny G Low; Yee Sin Leo; Feng Gu; Katja Fink Journal: PLoS One Date: 2011-12-22 Impact factor: 3.240
Authors: Chien-Hsing Chang; Jorma Hinkula; Meiyu Loo; Tina Falkeborn; Rongxiu Li; Thomas M Cardillo; Edmund A Rossi; David M Goldenberg; Britta Wahren Journal: PLoS One Date: 2012-07-23 Impact factor: 3.240